How can fever be differentiated from malignant hyperthermia clinically?

How can fever be differentiated from malignant hyperthermia clinically?

• A. Fever is a pharmacogenetic disorder triggered by anesthesia.
• B. Malignant hyperthermia is a regulated fever due to pyrogens.
• C. Fever is always fatal.
• D. Fever is a regulated rise in set point due to pyrogens; malignant hyperthermia is a pharmacogenetic disorder triggered by certain anesthetics causing uncontrolled calcium release and hypermetabolism.

Answer: (D)

Fever and malignant hyperthermia are governed by different mechanisms, and this difference is the key to telling them apart clinically. Fever is a regulated rise in the body’s temperature set point driven by pyrogenic signals—cytokines such as IL-1, IL-6, and TNF-α—that act on the hypothalamus to increase warmth production (shivering, vasoconstriction) until the set point returns to normal. It often follows infection or inflammation and generally develops over hours to days, not within minutes of anesthesia, and it does not produce the extreme, rapid metabolic crisis seen with MH. Malignant hyperthermia, on the other hand, is a pharmacogenetic disorder of skeletal muscle triggered by certain anesthetics. It causes an uncontrolled release of calcium from the sarcoplasmic reticulum via the ryanodine receptor, leading to sustained muscle activity, rapid heat production, rising CO2, acidosis, tachycardia, and often muscle rigidity. It is an acute crisis that can occur intraoperatively or shortly after exposure to triggering agents and demands immediate treatment with dantrolene and cessation of the triggering anesthesia. So, the best clinical distinction rests on the mechanism and context: fever is a regulated rise in set point due to pyrogens, whereas malignant hyperthermia is a pharmacogenetic, Ca2+-release–driven hypermetabolic crisis triggered by specific anesthetics.

Fever and malignant hyperthermia are governed by different mechanisms, and this difference is the key to telling them apart clinically. Fever is a regulated rise in the body’s temperature set point driven by pyrogenic signals—cytokines such as IL-1, IL-6, and TNF-α—that act on the hypothalamus to increase warmth production (shivering, vasoconstriction) until the set point returns to normal. It often follows infection or inflammation and generally develops over hours to days, not within minutes of anesthesia, and it does not produce the extreme, rapid metabolic crisis seen with MH.

Malignant hyperthermia, on the other hand, is a pharmacogenetic disorder of skeletal muscle triggered by certain anesthetics. It causes an uncontrolled release of calcium from the sarcoplasmic reticulum via the ryanodine receptor, leading to sustained muscle activity, rapid heat production, rising CO2, acidosis, tachycardia, and often muscle rigidity. It is an acute crisis that can occur intraoperatively or shortly after exposure to triggering agents and demands immediate treatment with dantrolene and cessation of the triggering anesthesia.

So, the best clinical distinction rests on the mechanism and context: fever is a regulated rise in set point due to pyrogens, whereas malignant hyperthermia is a pharmacogenetic, Ca2+-release–driven hypermetabolic crisis triggered by specific anesthetics.